We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed at $112.26 in the latest trading session, marking a +1.26% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.1% for the day. Elsewhere, the Dow gained 0.57%, while the tech-heavy Nasdaq lost 0.33%.
The HIV and hepatitis C drugmaker's shares have seen a decrease of 6.03% over the last month, not keeping up with the Medical sector's gain of 0.86% and the S&P 500's gain of 2.57%.
The investment community will be closely monitoring the performance of Gilead Sciences in its forthcoming earnings report. The company is predicted to post an EPS of $2.15, indicating a 6.44% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $7.42 billion, showing a 1.63% drop compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $8.1 per share and revenue of $28.75 billion, which would represent changes of +75.32% and -0.01%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Gilead Sciences. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 0.15% fall in the Zacks Consensus EPS estimate. Right now, Gilead Sciences possesses a Zacks Rank of #3 (Hold).
In terms of valuation, Gilead Sciences is currently trading at a Forward P/E ratio of 13.69. This represents a discount compared to its industry average Forward P/E of 19.95.
Investors should also note that GILD has a PEG ratio of 0.75 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.65.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note
Gilead Sciences (GILD - Free Report) closed at $112.26 in the latest trading session, marking a +1.26% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.1% for the day. Elsewhere, the Dow gained 0.57%, while the tech-heavy Nasdaq lost 0.33%.
The HIV and hepatitis C drugmaker's shares have seen a decrease of 6.03% over the last month, not keeping up with the Medical sector's gain of 0.86% and the S&P 500's gain of 2.57%.
The investment community will be closely monitoring the performance of Gilead Sciences in its forthcoming earnings report. The company is predicted to post an EPS of $2.15, indicating a 6.44% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $7.42 billion, showing a 1.63% drop compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $8.1 per share and revenue of $28.75 billion, which would represent changes of +75.32% and -0.01%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Gilead Sciences. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 0.15% fall in the Zacks Consensus EPS estimate. Right now, Gilead Sciences possesses a Zacks Rank of #3 (Hold).
In terms of valuation, Gilead Sciences is currently trading at a Forward P/E ratio of 13.69. This represents a discount compared to its industry average Forward P/E of 19.95.
Investors should also note that GILD has a PEG ratio of 0.75 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.65.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 97, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.